EUVIMEDScopri EUVIMED
Crossref

Fibroblast growth factor 21 serum levels in diabetes mellitus patients: assessment of their correlation with carbohydrate and lipid metabolism markers

Maria Trapali, Petros Karkalousos, Nikos Dogkas, George Albert Karikas

Review of Clinical Pharmacology and Pharmacokinetics - International Edition · 2025

DOI: 10.61873/bbdf1129 ↗

At a glance

Journal article in Review of Clinical Pharmacology and Pharmacokinetics - International Edition, 2025. Written by Maria Trapali and 3 co-authors. 33 references.

AbstractDati bibliograficiCiteRelated studies

Abstract (original language)

Background

Fibroblast growth factor 21 (FGF21 regulates several biochemical pathways such as glucose/fructose update, lipid oxidation, and insulin/glycogen sensitivity. Some beneficial effects of FGF21 on human body have been investigated, including weight loss and improved glycemia. It has been also suggested as a therapeutic agent for Diabetes Type 2.

Aim

Τhe aim of this study is to measure FGF21 serum levels in diabetes mellitus patients, compare them with FGF21 levels in healthy individuals and correlate them with age, carbohydrate and lipid metabolism markers. Methodology: In this study. FGF21 levels in 35 diabetics and 23 non-diabetics were correlated with Glucose, HBA1c, Cholesterol, Triglycerides, HDL-cholesterol, LDL-cholesterol concentrations.

Results

FGF21 concentration is doubled in diabetics. (both men and women). independently from the patients’ age. and it was statistically significant. No statistical correlation between FGF21 and other biochemical markers in diabetic and non-diabetic individuals. as well as within the two subgroups of participants aged 40 years old was recorded.

Conclusion

FGF21 is an important metabolic regulator, which its concentration was found increased in diabetics serum, in the present study, while no statistical correlation was found between FGF21, age of the participants and other biochemical markers.

Cite

APA

Trapali, M., Karkalousos, P., Dogkas, N., & Karikas, G. A. (2025). Fibroblast growth factor 21 serum levels in diabetes mellitus patients: assessment of their correlation with carbohydrate and lipid metabolism markers. Review of Clinical Pharmacology and Pharmacokinetics - International Edition. https://doi.org/10.61873/bbdf1129

Vancouver

Trapali M, Karkalousos P, Dogkas N, Karikas GA. Fibroblast growth factor 21 serum levels in diabetes mellitus patients: assessment of their correlation with carbohydrate and lipid metabolism markers. Review of Clinical Pharmacology and Pharmacokinetics - International Edition. 2025. doi:10.61873/bbdf1129

BibTeX
@article{Trapali2025,
  author = {Trapali, Maria and Karkalousos, Petros and Dogkas, Nikos and Karikas, George Albert},
  title = {Fibroblast growth factor 21 serum levels in diabetes mellitus patients: assessment of their correlation with carbohydrate and lipid metabolism markers},
  journal = {Review of Clinical Pharmacology and Pharmacokinetics - International Edition},
  year = {2025},
  doi = {10.61873/bbdf1129}
}
Start for free →